Relapsed/Refractory Diffuse Large B-cell Lymphoma

Oncology
4
Pipeline Programs
3
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
1
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

H
HutchmedChina - Hong Kong
2 programs
1
1
HMPL-760Phase 31 trial
HMPL-760 planned dose 1Phase 21 trial
Active Trials
NCT06601504Active Not Recruiting61Est. Nov 2026
NCT07409428Not Yet Recruiting240Est. Dec 2028
Karyopharm Therapeutics
1 program
1
SelinexorPhase 2/31 trial
Active Trials
NCT04442022RecruitingEst. Dec 2025
Antengene
AntengeneChina - Shanghai
1 program
1
ATG-010 and ATG-008Phase 11 trial
Active Trials
NCT05354362TerminatedEst. Feb 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
HutchmedHMPL-760
Karyopharm TherapeuticsSelinexor
HutchmedHMPL-760 planned dose 1
AntengeneATG-010 and ATG-008

Clinical Trials (4)

Total enrollment: 301 patients across 4 trials

NCT07409428HutchmedHMPL-760

A Phase III Study of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Relapsed/Refractory DLBCL

Start: Mar 2026Est. completion: Dec 2028240 patients
Phase 3Not Yet Recruiting
NCT04442022Karyopharm TherapeuticsSelinexor

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Start: Sep 2020Est. completion: Dec 2025
Phase 2/3Recruiting
NCT06601504HutchmedHMPL-760 planned dose 1

Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

Start: Nov 2024Est. completion: Nov 202661 patients
Phase 2Active Not Recruiting
NCT05354362AntengeneATG-010 and ATG-008

A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Start: Mar 2022Est. completion: Feb 2023
Phase 1Terminated

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 301 patients
3 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)